Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Young-PALETTA: Talazoparib +/- Atezolizumab in HR+/HER2- MBC
NCT04819243Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Aug 2021
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in breast cancer, sponsored by Samsung Medical Center. Started Aug 2021; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04819243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819243.